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HLA-DR molecules bind microbial peptides in an en-
dosomal compartment and present them on the cell
surface for CD4 T cell surveillance. HLA-DM plays
a critical role in the endosomal peptide selection
process. The structure of the HLA-DM–HLA-DR com-
plex shows major rearrangements of the HLA-DR
peptide-binding groove. Flipping of a tryptophan
away from the HLA-DR1 P1 pocket enables major
conformational changes that position hydrophobic
HLA-DR residues into the P1 pocket. These confor-
mational changes accelerate peptide dissociation
and stabilize the empty HLA-DR peptide-binding
groove. Initially, incoming peptides have access to
only part of the HLA-DR groove and need to compete
with HLA-DR residues for access to the P2 site and
the hydrophobic P1 pocket. This energetic barrier
creates a rapid and stringent selection process for
the highest-affinity binders. Insertion of peptide resi-
dues into the P2 and P1 sites reverses the conforma-
tional changes, terminating selection through DM
dissociation.
INTRODUCTION
T cells continuously patrol the body, sensing pathogen entry by
T cell receptor (TCR) recognition of proteolytic pathogen frag-
ments displayed on the cell surface bound to major histocom-
patibility complex (MHC) proteins (York and Rock, 1996). Only
a very small fraction of naive T cells in the repertoire recognizes
a given peptide (in mice, 20–200 cells) (Moon et al., 2007).
Thus, peptides acquired in intracellular compartments need to
be displayed by MHC proteins on the cell surface for extended
time periods for efficient recruitment of naive T cells into an anti-
microbial response. MHC class II (MHCII) molecules present
peptides from exogenous (and some internal) antigens to CD4
T cells that coordinate ensuing immune responses (Cresswell,C1994). The importance of CD4 T cells is illustrated by the severity
of AIDS in patients infected with HIV (Gandhi and Walker, 2002).
MHCII proteins aggregate in the absence of peptide (Germain
and Rinker, 1993; Rabinowitz et al., 1998), and the hydrophobic
peptide-binding groove is initially protected by invariant chain
(Roche and Cresswell, 1990b). Upon arrival in a late endosomal
compartment, invariant chain is degraded by several proteases,
leaving class-II-associated invariant chain peptides (CLIP) in the
peptide-binding groove (Riberdy et al., 1992; Roche and Cress-
well, 1991). DM (HLA-DM in humans, H2-DM in mice) catalyzes
CLIP dissociation, stabilizes empty MHCII proteins, and enables
rapid binding of microbial peptides generated by limited proteol-
ysis (Denzin and Cresswell, 1995; Denzin et al., 1996; Kropshofer
et al., 1997; Sherman et al., 1995; Sloan et al., 1995). A substan-
tial antigen-presentation defect is observed in human cell lines
and mouse strains deficient in DM expression (Fung-Leung
et al., 1996; Martin et al., 1996; Mellins et al., 1990; Miyazaki
et al., 1996; Morris et al., 1994).
DM can catalyze dissociation of any MHCII-bound peptide
and drives selection of peptides with the highest binding affinity
(Katz et al., 1996; Sloan et al., 1995; Weber et al., 1996). This
selection process (also referred to as ‘‘editing’’) has a major
impact on the peptide repertoire: DM extinguishes presentation
of many low-affinity peptides, while greatly enhancing presenta-
tion of high-affinity binders. For example, direct quantification of
peptides from hen egg lysozyme bound to I-Ak (a murine MHCII
protein) showed that the abundance of the immunodominant
peptide was reduced >1,100-fold in the absence of DM (Lovitch
et al., 2003). The structural mechanisms of DM-driven peptide
selection are not well understood. Mutagenesis experiments
identified large lateral surfaces of DM and MHCII proteins
involved in the interaction, and several mutants have implicated
a region in the vicinity of the peptide N terminus (Anders et al.,
2011; Doebele et al., 2000; Painter et al., 2011; Pashine et al.,
2003). A central problem is that most peptides bind with similar
on-rates to MHCII proteins, and many ‘‘low-affinity’’ peptides
have a half-life of several hours (Rabinowitz et al., 1998). It is
unknown how DM antagonizes presentation of peptides with a
t1/2 of <14 hr, while enhancing display of peptides with a t1/2
of >33 hr (Lazarski et al., 2006). The structure of a MHCII-DMell 151, 1557–1568, December 21, 2012 ª2012 Elsevier Inc. 1557
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complex is required to answer these questions, but this has
been a significant challenge for the field since the structures of
the individual proteins were reported (Brown et al., 1993; Fre-
mont et al., 1998; Mosyak et al., 1998; Stern et al., 1994). This
challenge is closely related to the function of DM, which is to
stabilize an unknown MHCII conformational intermediate that
binds peptides with rapid kinetics.RESULTS
Crystallization of the HLA-DM–HLA-DR1 Complex
We recently showed that DM does not detectably bind to HLA-
DR (a humanMHCII protein, abbreviated as DR) when the groove
is fully occupied by a covalently linked peptide. Rather, DM
binding requires truncation of several N-terminal peptide resi-
dues, including the anchor for the P1 pocket (Anders et al.,
2011). The hydrophobic P1 pocket is critical for stable peptide
binding to DR molecules: mutation of the P1 peptide side chain
to a polar residue prevents stable binding, whereas introduction
of an aromatic residue into a polyalanine sequence (with a single
lysine at a TCR contact residue) yields a high-affinity DR1 binder
(Jardetzky et al., 1990; Stern et al., 1994).
We reasoned that covalent linkage of an N-terminally trun-
cated peptide might enable crystallization of the DM-DR1
complex by trapping of a short-lived DM-sensitive DR1
conformer (Figure 1A). Soluble DR1 was first expressed with
a full-length low-affinity peptide (CLIPLow) and the linker between
the peptide C terminus and the N terminus of the DRb chain (Ko-
zono et al., 1994) was cut with endoproteinase GluC. CLIPLow
was then exchanged with an N-terminally truncated peptide,
which was trapped in the groove under mildly oxidizing condi-
tions by formation of a disulfide bond between a cysteine at
peptide position P6 and DR aV65C. This peptide was similar to
the influenza hemagglutinin (HA306-318) peptide previously used
to crystallize DR1 (Stern et al., 1994), but lacked three N-terminal
residues (P-2, P-1, and P1) and thus spanned from P2 to P11.
Initial cocrystallization experiments did not yield crystals. How-
ever, it was previously shown that the DM and DR transmem-
brane domains increase DM activity 200-fold to 400-fold by
properly positioning themolecules (Weber et al., 2001). Similarly,
attachment of leucine zippers to both b chains yielded an active
complex (Busch et al., 2002). We mimicked this positioning
effect by linking DRb and DMbC termini using sortase A, a trans-
peptidase from Staphylococcus aureus (Mao et al., 2004; Maz-
manian et al., 1999). This directional approach avoided formation
of homodimers of input proteins, a problem encountered during
attempts to link DM and DR through a disulfide bond. Sortase A
cleaves the peptide bond between threonine and glycine of
a C-terminal LPATG motif and forms a covalent bond with theFigure 1. Overview of the HLA-DM–HLA-DR1 Complex
(A) Generation of a covalent DM-DR1 complex with a linked peptide that lacks th
(B and E) Top view of the DM-DR1 complex shows the DM interaction site on the
DMb yellow, DRa cyan, and DRb blue. Peptide and the DR aV65C covalent atta
(C, D, and F) Side views of the DM-DR1 complex, with contact residues of DR1 (C
DMa chains. The C termini of DRb and DMb chains are indicated (C). (F) The locati
arrow.
See also Figure S1 as well as Movies S1 and S2.
CN-terminal amino group of an oligo-glycine. We attached the sor-
tase tag to DRb and linked a peptide with N-terminal glycine resi-
dues to an introduced cysteine at the C terminus of the DMb
extracellular domain. The linked DM-DR1 complex crystallized
under a variety of different conditions, and structureswere deter-
mined for crystals grown at pH 5.5 and 6.5. DM has optimal
activity at an acidic pH (Denzin and Cresswell, 1995), and the
description therefore focuses primarily on the pH 5.5 structure.
Overview of the HLA-DM–HLA-DR1 Complex
The structure of the complex of DM and DR1 was determined at
a resolution of 2.6 A˚ in space group P212121 (one molecule in
the asymmetric unit). The structure was refined to final R/Rfree
factors of 19.7/24.1% (Table S1). An example of electron density
at the interface is shown in Figure S1A. There are no crystal
contacts involving the peptide or DR1 helices in relevant parts
of the groove (Figures S1C and S1D; Table S2). No electron
density for the linker is observed in either of the two structures.
The distance between the C termini of DRb and DMb is 19.9 A˚,
and no electron density is visible for 25 amino acids and a malei-
mide group connecting the C termini (extended length of75 A˚).
The ectodomains of DM and DR1 are oriented parallel to each
other, consistent with their colocalization on membranes in late
endosomal compartments (Figures 1C and 1D). The area of the
DM-DR1 interface is 1,595 A˚2 and the shape complementarity
is 0.644. The interface is dominated by the a chains of DM and
DR1 (66% of interface) (Figure 1C and Movies S1 and S2). DM
binds to a lateral surface of the DRa1 domain, close to the
peptide-binding groove, without contacting the DRb1 domain
or obstructing theopenendof thegroovewherepeptideN termini
can exit (Figures 1B, 1E, and 1F). In fact, a large cavity is present
at this site, explaining how long antigen fragments can bind
before being trimmed to shorter peptides (Castellino et al.,
1998; Nelson et al., 1997). The interface with the DRa1 domain
is formed by DMa1 and, to a lesser extent, DMb1 (Figures 1B,
1C, and 1E; Figures S2A–S2D). A small interface among the b2
domains of DM and DR (19.5% of total) stabilizes the overall
topology (Figure S2E). Previously reported mutations localize to
the DM-DR interface (Anders et al., 2011; Doebele et al., 2000;
Painter et al., 2011; Pashine et al., 2003), providing independent
support for the structure (Figures 2A and 2B). The linked peptide
spans fromP2 to P11, but unambiguous density is only observed
for theP5–P11 segment (Figures 1Band1E). Thus,more than half
of the binding groove is largely devoid of peptide.
Flipping of DR aW43 from the P1 Pocket toward DM
In the previously reported DR1/HA306-318 structure (Protein Data
Bank ID code [PDB] 1DLH) (Stern et al., 1994), DR aW43 forms
a lateral wall of the P1 pocket and interacts with the P1 tyrosineree N-terminal residues.
DRa chain and a partially empty peptide-binding groove. DMa is colored red,
chment site are colored orange.
) or DM (D) presented as surfaces, emphasizing interactions between DRa and
on of the peptide N terminus in the DR1-HA306-318 structure is indicated with an
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Figure 2. Key Residues Involved in the DM-DR1 Interaction
(A) Molecules are shown in cartoon representation, and interacting residues are surface rendered. Mutations that affect the interaction are indicated.
(B) List of DM and DR mutants (new and previously identified), grouped by functional activity (new mutations are underlined). These residues are located at the
DM-DR1 interface, except DR aP96 (mutation introduces glycan), DM bA55 (residue not surface exposed), and DM bE8 (mutation to lysine may affect DM
conformation). DR aF51 and aE55 have moved into the peptide-binding groove in the DM-DR1 complex, as described in Figures 4 and 5.
(legend continued on next page)
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Figure 3. HLA-DR aW43 Is Critical for HLA-
DM Binding
(A) Structure of DR1-HA306-318 complex showing
packing interactions of DR aW43 (red) with
hydrophobic residues, including peptide P1 tyro-
sine (green).
(B) W43 stabilizes P1 pocket in DR1-HA306-318
(white) but is rotated away from the P1 pocket
in the DM-DR1 complex (red). Conformational
changes in DM-DR1 (cyan) compared to DR1-
HA306-318 (yellow) include movement of b strands
and extension of the helix to include DR a52–55.
(C) Overall conformation of DR-binding groove in
DM-DR1 complex compared to DR1-HA306-318.
(D) Hydrogen bonding network established by DR
aW43 and aK38/aE40.
(E) Pocket on DM surface occupied by DR aW43.
(F) Effect of DM aN125 mutations on rate of
peptide binding, measured using a real-time
peptide-binding assay based on fluorescence
polarization (FP). Binding of a fluorescent peptide
to a large protein reduces its tumbling rate in
solution (measured in mP units). Graph shows
change in rate of initial peptide binding (mPmin1),
measured in triplicates. Error bars represent
mean ±SEM.
See also Figure S3.of the HA peptide (Figure 3A). In addition, it stabilizes residues in
the vicinity of the P1 pocket through many interactions. In the
DM-DR1 complex, aW43 is rotated out of the groove and its
indole ring nitrogen forms a hydrogen bond with DM aN125
(Figures 3B and 3D; Figures S3A–S3D). DM aN125 lies on the
edge of a hydrophobic pocket with which the indole ring inter-
acts (Figure 3E; Table S2). The interaction between DR aW43
and DM aN125 represents a key feature of the complex. Muta-
tion of DM aN125 to alanine results in an almost complete loss
of DM activity (Figure 3F; Figure S3E), and responsiveness to
DM is greatly reduced by a conservative DR aW43F mutation
(Anders et al., 2011). Also, both residues are entirely conserved
among DMA and DRA homologs across all examined species,
including chicken (Figure 2C). DR aW43 is even conserved in
coelacanth, an ancient fish species that was thought to be
extinct before its rediscovery. DR aW43 is also conserved
among the polymorphic human DQA and DPA genes (except
DPA1*01:10, possibly a loss-of-function variant).(C) Conservation of key contact residues. Alignments focus on the DR1 a1 domain (residues 31–61) and two
Interacting residues are colored blue (DRa) and yellow (DMa). Sequences were retrieved from http://www
residues are highlighted in red; DR residues that have moved into the groove are colored green.
See also Figure S2.
Cell 151, 1557–1568, DeIn MHC class I (MHCI) molecules, the
entire peptide-binding groove is flanked
by two long a helices (a1 and a2) (Bjork-
man et al., 1987). In MHCII-peptide
complexes, the a chain does not form
a helix along the entire length of the
peptide. Rather, DRa chain residues 52–
55 form a short strand parallel to thebound peptide (Figure 3A) which is stabilized by conserved
hydrogen bonds to the backbone of N-terminal peptide residues
(P-2, P-1, and P1) (Stern et al., 1994). This entire region is sub-
stantially changed in the DM-DR1 complex. The strand and the
neighboring 310 helix (DR a46–50) (Figure 3A) are merged into
a helix (Figures 3B and 3C). Essentially, this results in formation
of an extended helix fromDR a46 to 77, with a break at A56-G58.
This conformational change would not be possible without the
DR aW43 flip, which creates the required void. The conforma-
tional change is facilitated by loss of stabilizing interactions of
aW43with neighboring structural elements, including the b sheet
floor of the groove, the 310 helix (DR a46–50), and the DR a52–55
strand (Figures 3A and 3B).
In addition, substantial conformational changes are observed
on the floor of the peptide-binding groove in the vicinity of the P1
pocket. In the DR1-HA306-318 structure, strands S3 and S4 (resi-
dues a29–35 and a39–44, respectively) are in a strained confor-
mation. In the DM-DR1 structure, both strands have movedsegments of DMa (residues 91–101 and 121–141).
.ensembl.org (June 2012). Key DRa-DMa contact
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Figure 4. Large Conformational Changes Stabilize the Empty
Binding Groove around the P1 Pocket in the DM-DR1 Complex
(A) Surface representation of DR1 with fully bound HA306-318 peptide showing
aF51 (yellow), aF54 (green), and aE55 and bN82 (both red). aF51 is pointing out
of the groove and aE55 is located outside the binding site. DR bH81 (dotted
line) is rendered transparent to improve visibility of DR bN82. DR b82 forms
bidentate hydrogen bonds with the peptide backbone at P2.
(B) In the DM-DR1 complex, aF51 has moved into the P1 pocket, stabilizing
this hydrophobic site. DR aE55 has moved into the groove where it forms
a water-mediated hydrogen bond with DR bN82.
See also Figure S4.away from the DRa1 helix and toward the main b sheet platform
(Figure 3B), which positions two key residues of the S4
strand and S3/S4 loop (DR aE40 and aK38, respectively) at the
interface with DM (Figure 3D; Figures S1A and S1B). These
charged residues form an extended hydrogen-bonding network
that includes DM aD183, aR98, and aH180 (Figure 3D; Figures
S3F and S3G). The importance of this network is highlighted
by previous mutagenesis data: mutation of DM aR98 greatly
impairs DM function (Anders et al., 2011), whereas mutation of
DR aE40 results in unresponsiveness to DM (Doebele et al.,
2000).
Stabilization of the P1 Pocket by DR aF51 and bF89
Previous mutagenesis studies showed that mutation of DR aF51
to alanine abrogates responsiveness to DM (Doebele et al.,
2000; Painter et al., 2011). F51 points out of the groove in the
DR1-HA306-318 structure (Figure 4A), which suggested that it
represents an important DM interaction site close to the pep-
tide N terminus. However, the structure of the DM-DR1 complex
reveals a dramatic repositioning of F51 into the P1 pocket (a 13A˚1562 Cell 151, 1557–1568, December 21, 2012 ª2012 Elsevier Inc.movement, measured from the tip of the phenyl ring) (Figures 4B
and 5B; Figure S4). This movement results from folding of the
DR a52-55 strand into a helical conformation and the accompa-
nied helix tilt, as described above (Figures 3B and 3C). In the
DM-DR1 complex, F51 thus stabilizes the most hydrophobic
site of the groove (Figures 4B and 5B). The P1 area is further
stabilized by a conformational change in the DR b86–91 segment
that positions bF89 near the P1 pocket where it closely interacts
with DR aF51 (Figures 5C and 5D). This explains why empty DR
molecules are stable when bound to DM (Kropshofer et al.,
1997).
The P1 pocket of DR1 is optimally filled by bulky aromatic
residues, and we tested DR aF51 mutants for DM binding (Fig-
ure 5E) and DM-catalyzed peptide exchange (Figure 5F). The
size of the hydrophobic DR a51 residue was critically impor-
tant for DM binding, with a tryptophan at this position having
more activity than the wild-type phenylalanine, whereas smaller
leucine and valine mutants were less responsive (some HLA-DR
alleles have a smaller P1 pocket, which accommodates a
phenylalanine residue but not tyrosine or tryptophan). A previ-
ously reported DRbG86Ymutation fills the P1 pocket and would
prevent the conformational changes we describe for the DM-
DR1 structure, consistent with the observation that this mutation
greatly reduces responsiveness to DM (Chou and Sadegh-Nas-
seri, 2000).
DR aE55 also moves into the groove where it forms a water-
mediated hydrogen bond with DR bN82 (Figure 4B; Figure S5).
The bidentate hydrogen bonds formed by DR bN82 and the
P2 peptide backbone (Figure 4A) make a crucial contribution
to stable peptide binding: mutation of this residue accelerates
peptide dissociation from DR1 3,000-fold (Zhou et al., 2009).
Movement of DR aE55 into the groove may therefore contribute
to peptide dissociation.
Effect of pH on DM-DR1 Conformation
DM activity is regulated by pH, with an optimum in the 5.0–5.5
range of late endosomes. We determined a second structure
at pH 6.5 in order to examine how pH affects the DM-DR1
interaction (Figure 6; Tables S1 and S3). Surface plasmon reso-
nance (SPR) studies demonstrated DM binding by DR1 with
a linked P2-P11 peptide at pH 6.5, with an 3-fold lower affinity
compared to pH 5.5 (Figures S6A and S6B). The complex crys-
tallized in the same space group (P212121, one molecule in
the asymmetric unit), and the unit cell dimensions are similar
to the pH 5.5 condition. Overall, the pH 6.5 structure is very
similar to the pH 5.5 structure with an overall root-mean-
square deviation (rmsd) of 0.44. Also, the overall interface with
DM is similar, including the interaction of DR aW43 and DM
aN125.
However, several major differences are evident. Very little
density is present for the P2–P4 peptide segment in the pH 5.5
structure (with some residual density in the P4 pocket) (Fig-
ure 6A). This peptide segment is presumably in rapid motion
and may bind at a low occupancy. Also, the P5 residue is
pointing out of the groove and even the linked P6 residue is
elevated. Mass spectrometry analysis confirmed the presence
of the entire P2–P11 peptide in crystals grown at pH 5.5 (data
not shown). In contrast, at pH 6.5, electron density is observed
Figure 5. Stabilization of P1 Site by DR aF51
and DR bF89
(A) Top view of DR1-HA306-318 complex, with
peptide P1 tyrosine (green) in P1 pocket.
(B) DR aF51 moved into highly hydrophobic P1
pocket in DM-DR1 complex.
(C and D) DR bF89 (red) also moved into groove in
DM-DR1 complex, stabilizing aF51. Position of DR
bF89 (*) in DR1-HA306-318 complex is indicated in
gray (C).
(E) SPR analysis of DM binding by DR aF51
mutants: injection of DR-CLIP (stage 1, DR bind-
ing), buffer (stage 2, dissociation of empty DR),
and peptide (stage 3, peptide-dependent disso-
ciation of DM-DR complex).
(F) Kinetics of peptide binding by DR aF51mutants
±DM. Peptide binding was examined in a real-time
fluorescence polarization (FP) readout (mP units),
as explained in Figure 3F.
See also Figure S5.for all peptide residues at full occupancy (Figure 6B), and the
conformation of the peptide backbone is similar to the DR1-
HA306-318 structure. These pH-dependent differences in peptide
electron density were confirmed by generating simulated an-
nealing omit maps (Fo-Fc) in which the peptide model was
omitted (data not shown).
Interestingly, DR aF51 is not located in the P1 pocket in the
pH 6.5 structure, but at an intermediate position compared to
the pH 5.5 DM-DR1 and DR1-HA306-318 structures (Figures 6C
and 6D). DR bF89 is located outside the groove and does
not stabilize DR aF51 in the P1 pocket (Figures 6C and 6D).
Also, DR aE55 is present in a different rotamer in the pH 6.5
structure that does not sterically hinder access of peptide P2
to DR bN82 but rather forms a hydrogen bond with P2 (Fig-
ure 6C). The pH 6.5 structure thus shows an intermediate
conformation of the DM-DR complex in which the P1 pocket is
not fully stabilized and DR aE55 does not sterically hinder the
P2 peptide residue.
A pair of acidic DM residues, bD31 and bE47, was previously
shown to contribute to the pH dependence of DM activity (Nich-
olson et al., 2006). Both residues interact with DR1 in the pH 5.5
structure, but DM bE47 is located outside the interface at pH 6.5
(Figures 6E and 6F; Figures S6E–S6J; Table S3). These changesCell 151, 1557–1568, Deaffect the position of several DR residues,
including DR aQ57, aE55, and aF54 (Fig-
ures 6E and 6F; Figures S6E–S6J). The
relevance of these interactions is sup-
ported by a DR aQ57A mutation, which
reduces DM activity in a pH-dependent
manner (Figure S6D).
Model of DM-Driven Peptide
Selection
Proteolytic degradation of invariant
chain leaves CLIP in the DR peptide-
binding groove (Figure 7, step 1). No
DM binding is detectable when the DR-
binding groove is fully occupied bya peptide. The peptide N terminus needs to dissociate from
the groove, a step that may be closely linked with flipping of
DR aW43 (highlighted in red) away from the P1 pocket (step 2).
The flipped DR aW43 side chain becomes a key DM interaction
residue, and three DR1 residues move into the groove (step 2 to
step 3). In the DM-bound state, these DR1 residues (DR aF51,
bF89, and aE55, circled) stabilize the empty groove. Incoming
peptides bind with rapid kinetics, but part of the groove initially
remains inaccessible, driving a rapid peptide exchange process
(step 4). Only peptides that successfully compete with DR resi-
dues for access to the P2 site and the P1 pocket are stably
bound. Full occupancy of the groove reverses the conforma-
tional changes associated with DM binding and results in DM
dissociation (step 5). DM thus binds an otherwise labile transition
state in which a peptide is partially bound in the groove. It
stabilizes such conformers and thereby reduces the energetic
barriers associated with peptide dissociation and binding
(Weber et al., 1996).
DISCUSSION
The two structures provide mechanistic insights into three
central aspects of DM function: DM-catalyzed peptidecember 21, 2012 ª2012 Elsevier Inc. 1563
Figure 6. Conformational Differences between pH 6.5 and pH 5.5 DM-DR1 Structures
(A and B) Peptide electron density at pH 5.5 (A) and pH 6.5 (B).
(C) Differences in position of key DR residues at pH 6.5 (colored) and pH 5.5 (gray); pH 5.5 residues (*).
(D) Space filling model of hydrophobic DR residues of P1 pocket in pH 6.5 structure, DR aF51 (yellow) located partially in P1 site, and bF89 (red) outside the
groove.
(E and F) Differences in the interaction of an acidic pair (DMb D31-E47) with DR1 at pH 5.5 (E) and pH 6.5 (F).
See also Figure S6.dissociation, DM-dependent stabilization of empty DR, and
rapid selection of high-affinity peptides by the DM-DR complex.
How Does DM Accelerate Dissociation of Peptides
from DR?
A series of studies showed that DM greatly accelerates dissoci-
ation of CLIP and other peptides from DR molecules, but the
structural mechanisms have remained largely unclear (Denzin
and Cresswell, 1995; Sherman et al., 1995; Sloan et al., 1995).
We previously reported that DM binding can only be detected
when the peptide N terminus has dissociated from the DR
groove (Anders et al., 2011), and the structure provides a mech-
anistic explanation for this finding. Loss of hydrogen bonds
with the peptide backbone (at P-2, P-1, and P1) is required for
folding of the DR a52–55 segment into a helical conformation,
and the peptide P1 anchor residue needs to vacate the P1
pocket for movement of the DR aF51 side chain into this hydro-
phobic site.
The structures suggest that flipping of DR aW43 away from the
P1 pocket and dissociation of the peptide N terminus are closely
linked events. Rotation of the DR aW43 side chain out of the
groove should destabilize the P1 pocket and favor dissociation
of the peptide N terminus. Alternatively, if the N terminus disso-
ciates first, then the resulting loss of hydrophobic packing inter-
actions with the P1 side chain should facilitate rotation of the DR
aW43 side chain away from the P1 pocket. In the absence of DM,
the most likely outcome is a rapid reversal of these confor-
mational changes, depending on the DR-binding affinity of the
more C-terminal parts of a peptide. The structures further
suggest that flipping of DR aW43 is important for subsequent
conformational changes. In the structure of the DR1-HA306-3181564 Cell 151, 1557–1568, December 21, 2012 ª2012 Elsevier Inc.complex, DR aW43 forms lateral packing interaction with the
b sheet floor of the groove (DR aF32), the 310 helix (DR aF48),
and the DR a52–55 strand (Stern et al., 1994). In the DM-bound
state, substantial conformational changes are observed for all
three structural elements. The most significant change is the
formation of a longer tilted a-helical segment stretching from
DR a46–55. DR aW43 would clash with this helical segment if
its side chain would notmove away from the P1 pocket, suggest-
ing that the DR aW43 flip is an early step in this sequence. This
conformational change repositions DR aF51 into the P1 pocket,
a step that is critical for DM binding, as shown by extensive
mutagenesis experiments.
DM and DR molecules are localized on the same endosomal
membranes, prepositioning them for the lateral interaction
mode seen in the structure (Pashine et al., 2003). Indeed, the
presence of DM and DR transmembrane domains enhances
DM activity 200- to 400-fold (Busch et al., 1998; Weber et al.,
2001). It is possible that low-affinity, short-lived binding interac-
tions can occur between the membrane-proximal immunoglob-
ulin domains of DM and DRwhen both molecules are membrane
tethered. The DM a1 and b1 domains may thus be able to rapidly
interact with a short-lived DR conformer in which the peptide N
terminus is outside the groove and DR aW43 is available for
binding to DM aN125. Both residues are fully conserved among
all examined species, and their importance in the DM-DR inter-
action is further underscored by mutagenesis experiments.
Comparison of the pH 5.5 and 6.5 structures identifies another
feature relevant for DM-catalyzed peptide dissociation. A large
body of work has shown that spontaneous peptide dissociation
fromMHCII molecules is greatly accelerated by a low pH, even in
the absence of DM (Reay et al., 1992). Furthermore, DM activity
Figure 7. Model for Key Steps in DM-DR
Interaction
(Step 1) CLIP is bound in DR groove and DR aW43
(red, arrow) stabilizes P1 pocket. (Step 2) Peptide
N terminus dissociates from DR groove and DR
aW43 rotates away from the P1 pocket, becoming
available for interaction with DM. Other DR resi-
dues (arrows) move into groove during transition
to DM-bound state. (Step 3) DM stabilizes empty
DR, and DR aF51 and bF89 protect the hydro-
phobic P1 pocket. (Step 4) Rapid binding of
peptides to partially accessible groove; peptides
that do not successfully competewith DR residues
(yellow) for P2 site and P1 pocket are not stably
bound. (Step 5) Binding of the peptide N terminus
reverses conformational changes and results in
DM dissociation.is highly pH dependent, with an optimum at the pH of late endo-
somes (pH 4.5–5.5) (Sloan et al., 1995). Very little electron
density is observed for the P2–P4 peptide segment in the pH
5.5 structure, but the entire covalently linked peptide (from P2
to P11) is bound at pH 6.5. Of particular interest is the pair of
acidic DMb D31-E47 residues that interact with each other at
pH 5.5, but have moved apart at pH 6.5. Mutation of both
residues to the corresponding carboxamide (DMb D31N-E47Q)
was previously shown to extend the pH range of DM activity
(9-fold increase of DM activity at neutral pH) (Nicholson et al.,
2006). These data suggest that the DMb D31-E47 pair may be
(partially) protonated at pH 5.5, but deprotonated at a higher
pH. These changes affect the interaction with DRa, in particular
the conformation of the critical DR a54–57 segment: only at the
lower pH, the side chain of DR aE55 forms a water-mediated
hydrogen bondwith DR bN82. In this position, DR aE55 sterically
hinders an interaction between the peptide P2 residue and
DR bN82 and prevents formation of energetically important
hydrogen bonds (Zhou et al., 2009).
The following steps are thus important for peptide dissocia-
tion: Short-lived DM-sensitive DR conformers form following
dissociation of the peptide N terminus from the DR groove. Rota-
tion of DR aW43 out of the groove creates a key DM interaction
site andmakes other conformational changes energetically more
favorable. Rebinding of the peptide N terminus is inhibited by
movement of DR residues into the P1 pocket (DR aF51 and
bF89). Peptide dissociation is further accelerated by loss ofCell 151, 1557–1568, Dehydrogen bonds between the peptide
backbone at P2 and DR bN82. This
scenario is supported by the two struc-
tures and a large body of functional
data. It should be noted that these steps
are unlikely to always occur in a particular
sequence. For example, a peptide may
completely dissociate prior to DMbinding
if it has a very low affinity for the DRmole-
cule. However, alternative conforma-
tions, including inactive states of the DR
molecule, become more likely when
a large part of the groove is devoid ofpeptide (Painter et al., 2008; Rupp et al., 2011). Given that DM
can accelerate peptide dissociation >1,000-fold (Weber et al.,
1996), it must bind to most DR molecules prior to complete
peptide dissociation.
How Does HLA-DM Stabilize Empty MHC Class II
Molecules?
Empty DR1 rapidly transitions into an inactive state (the half-
life is allele dependent, 5 min for DR1), yet DR molecules
maintain a highly peptide-receptive conformation in the pres-
ence of DM (Grotenbreg et al., 2007; Kropshofer et al., 1997;
Rabinowitz et al., 1998). DM-DR complexes have been purified
from cells and were found to be largely devoid of peptide (Den-
zin et al., 1996; Kropshofer et al., 1997; Sanderson et al., 1996).
Furthermore, SPR experiments showed that empty DR dissoci-
ates from DM with very slow kinetics (Anders et al., 2011).
Movement of DR aF51 and bF89 into the P1 site protects the
most hydrophobic part of the groove and prevents transition
into alternative, inactive conformers with a tendency to aggre-
gate. Stable empty MHCII-DM complexes are functionally im-
portant: DM deficiency results in an antigen-presentation defect
even for MHCII proteins that do not require DM for CLIP disso-
ciation, due to a low affinity for CLIP (Koonce et al., 2003). Rapid
binding to MHCII molecules protects proteolytic fragments
from degradation, and proteolytic trimming can occur after bind-
ing to a MHCII molecule (Castellino et al., 1998; Nelson et al.,
1997).cember 21, 2012 ª2012 Elsevier Inc. 1565
How Does DM Enable Rapid Selection of the Highest-
Affinity Peptide Ligands?
The mechanisms of DM-catalyzed peptide selection have been
difficult to explain. All peptides have similar on-rates and differ
primarily in their off-rates (Rabinowitz et al., 1998). The structure
implies how peptide editing can occur with rapid kinetics, even
though peptides have a very long half-life (many hours or days)
when fully bound in the groove (Jardetzky et al., 1990; Roche
and Cresswell, 1990a). In the pH 5.5 DM-DR1 structure, the
two most important structural elements for stable peptide
binding are inaccessible: the P1 pocket and the DR bN82 side
chain. Incoming peptides thus need to compete with DR1 resi-
dues for access to these binding sites, which creates an ener-
getic and kinetic barrier for full occupancy of the groove. This
mechanism ensures that high-affinity peptides, which are
present in limited quantities in the loading compartment (Ger-
main and Hendrix, 1991), are not outcompeted by low-affinity
peptides. This proposed mechanism is supported by functional
experiments in which DM and DR1 were linked by leucine
zippers. Peptides dissociated with very rapid kinetics from this
linked complex: CLIP with a t1/2 of 10 s and HA306-318 with a t1/
2 of 2 min (note that HA306-318 has a t1/2 of 1 month in the
absence of DM) (Busch et al., 2002).
Structural features along the entire peptide are relevant for
DM editing (Belmares et al., 2002; Weber et al., 1996), even
though DM interacts with a site close to the peptide N terminus.
Anchor residues in the middle and C-terminal part of the
peptide need to properly engage available pockets (such as
P4, P6, and P9) during the initial stages of binding, positioning
peptides to access DR bN82 and the P1 pocket. Peptides with-
out a hydrophobic P1 anchor do not induce DR dissociation
from DM and are subject to continued editing (Anders et al.,
2011). This mechanism explains how DM catalyzes selection
of peptides with a very long half-life for presentation on the
cell surface.
Which Mechanisms Limit DM-Catalyzed Displacement
of High-Affinity Peptides?
SPR experiments have shown that peptides induce dissociation
of a complex of DM and empty DR, depending on the affinity of
the peptide for the DR molecule (Anders et al., 2011). This result
can now be explained based on the new structures: the peptide
P1 anchor and DR aF51 compete for access to the same DR1
pocket. DM binding is abrogated by the DR aF51A mutation.
This suggests that insertion of a hydrophobic peptide side chain
into the P1 pocket is one of the key steps that trigger DM disso-
ciation from the complex. High-affinity peptides thus rapidly
terminate editing, and rebinding of such DR-peptide complexes
to DM occurs with slow kinetics (Anders et al., 2011).
Relevance for MHCI Molecules
MHCI molecules bind peptides in the endoplasmic reticulum
(ER) that are generated by the proteasome and transported
into the ER by the TAP (transporter associated with processing)
heterodimer. Empty MHCI molecules become part of the
‘‘peptide-loading complex’’; they are bound by calreticulin and
the disulfide-linked tapasin-ERp57 dimer, which also recruits
them to the TAP heterodimer (Chen and Bouvier, 2007; Peaper1566 Cell 151, 1557–1568, December 21, 2012 ª2012 Elsevier Inc.and Cresswell, 2008; Sadegh-Nasseri et al., 2008; Wearsch
and Cresswell, 2007). Even though all involved proteins, the
compartment, and the pH are different, the essential problem
for peptide loading is the same: how are empty molecules stabi-
lized in a manner that enables rapid selection of the highest-
affinity ligands? The tapasin-ERp57 heterodimer appears to
stabilize the N-terminal part of the a2 helix of MHCI molecules
(which flanks the C-terminal part of peptides) (Dong et al.,
2009). Also, monoclonal antibodies (such as mAb 64-3-7) have
been identified that bind to peptide-receptive but not peptide-
loaded states of a MHCI molecule. The 64-3-7 antibody recog-
nizes a short peptide segment of the MHCI heavy chain corre-
sponding to a 310 helix (residues 46–52) in the vicinity of the
peptide N terminus. In the peptide-loaded state, a conserved
tryptophan residue (W51) and M52 buttress invariant tyrosine
residues (Y59 and Y171) at the amino-terminal end of the pep-
tide-binding groove. W51 and M52 become solvent-exposed
in the peptide-receptive form, apparently by movement of the
310 helix containingW51 andM52 (Mage et al., 2012). Conforma-
tional changes in the vicinity of the peptide N terminus may thus
be relevant for not only peptide-receptive states of MHCII but
also MHCI molecules.
EXPERIMENTAL PROCEDURES
Crystallization, Data Collection, and Structure Determination
Crystallization trials were performed by hanging drop vapor diffusion at
room temperature. Crystals appeared under a variety of different conditions.
Crystals from two conditions were used for structure determination: (1) 0.2 M
sodium acetate, 0.1 M sodium citrate (pH 5.5), 10% PEG 4,000; (2) 0.1 M
MES (pH 6.5), 6% PEG 20,000. Crystals were cryoprotected using either
30% (v/v) ethylene glycol or 20% (v/v) glycerol and flash-frozen in liquid
nitrogen. Diffraction data were collected at 100 K at the NE-CAT beamline
24-ID-E while performing a continuous vector scan over the crystal. The
data were processed with the HKL2000 program, and the structure was
determined by molecular replacement using HLA-DR1 (1DLH) and HLA-DM
(1HDM) as search models (for details, see Extended Experimental Proce-
dures). Atomic coordinates and structure factors for the reported crystal
structures have been deposited under PDBs 4FQX (pH 5.5) and 4GBX
(pH 6.5).
Biacore Analysis of DM-DR Binding
Mutations were introduced into HLA-DR15 (DRA*01:01,DRB1*15:01) because
a large body of data is available for comparison (Anders et al., 2011). The
sequence of the DRa chain is identical for DR1 and DR15. DR15-CLIP binding
to DM was measured by SPR using a Biacore 3000 instrument (GE Health-
care). Wild-type and mutant DM were biotinylated at a BirA site on the C
terminus of DMa and captured on a streptavidin surface (500 response units
[RU]). DR15-CLIP complexes were diluted in running buffer (50 mM citrate-
phosphate [pH 5.35], 150 mM NaCl, 0.06% C12E9 detergent) immediately
prior to injection. DR15-CLIP WT and indicated mutants were injected at
25 ml/min (stage 1, DR binding to DM), followed by running buffer (stage 2,
dissociation of empty DR from DM) and a peptide (myelin basic protein,
MBP residues 85–99, 1 mM) that binds to DR15 (stage 3, dissociation of DR-
peptide from DM) (300 s for each stage) (Anders et al., 2011). Experiments
were performed at 30C. Measurements from the reference flow cell (immobi-
lized DM double mutant, DMa R98A-R194A) were subtracted from experi-
mental values.
Peptide-Binding Assay
A real-time assaywas used to assess binding of a fluorescent peptide to DR15,
employing a fluorescence polarization (FP, mP units) readout (Nicholson et al.,
2006). The linker connecting the CLIP peptide to the N terminus of the DRb
chain was cut with thrombin (1 hr, 20 U/mg, at room temperature). DR15-CLIP
complexes (150 nM) were incubated ±DM (typically 25 nM) in the presence of
a high-affinity Alexa-488-labeled MBP85-99 peptide (30 nM) at 30
C. Assays
were set up in a volume of 40 ml in black polystyrene 384-well plates (Corning,
NY, USA) in 50 mM citrate (pH 5.2) at 30C (triplicates). Initial binding rates
were calculated using Graphpad 5.0.
The Extended Experimental Procedures describe details on the formation of
the DM-DR1 complex not described in the Results and Figure 1, as well as
structure determination.ACCESSION NUMBERS
Atomic coordinates and structure factors for the reported crystal structures
have been deposited in the Protein Data Bank with ID codes 4FQX (pH 5.5)
and 4GBX (pH 6.5).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, three tables, and two movies and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2012.11.025.
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